Key Highlights
- Amgen has committed an extra $300 million to enhance its biologics production facility located in Juncos, Puerto Rico.
- This site supplies pharmaceutical products to over 60 nations worldwide and will undergo capacity expansion.
- The investment brings Puerto Rico’s total to more than $650 million in commitments announced within the last year.
- Across the United States, Amgen’s manufacturing pledges in the past year surpass $3.65 billion, spanning Puerto Rico, Ohio, California, and North Carolina.
- This strategic move arrives amid pharmaceutical companies navigating President Trump’s executive directive warning of 100% tariffs on imported brand-name drugs.
Amgen (AMGN) experienced a 1.54% decline on Monday following the biotechnology company’s announcement of an additional $300 million commitment to enhance its biologics production site in Juncos, Puerto Rico.
This expansion project focuses on increasing manufacturing output and implementing cutting-edge production technologies at the location, which has operated continuously since 1992.
The Juncos manufacturing complex presently ships biologic therapies to more than 60 nations globally. This capital infusion will bolster current manufacturing positions at the facility while generating hundreds of temporary construction opportunities.
Chief Executive Officer Robert Bradway stated that this expansion demonstrates Amgen’s “ongoing dedication to manufacturing in America” and aims to safeguard domestic pharmaceutical supply networks and ensure patient medicine availability.
Puerto Rico’s Governor Jenniffer González Colón praised the announcement, noting that the investment validates the effectiveness of policies supporting the territory’s biopharmaceutical industry.
This $300 million allocation supplements the $650 million Amgen previously pledged to Puerto Rico operations during the past twelve months, which was projected to generate approximately 750 employment opportunities.
Broader Domestic Manufacturing Strategy
This newest financial pledge represents one component of an extensive nationwide investment initiative. Throughout the previous year, Amgen has committed $900 million toward Ohio operations, $600 million for establishing a science and innovation hub in California, and over $1.5 billion in North Carolina facilities.
When combined with the recently announced Puerto Rico investment, Amgen’s aggregate U.S. manufacturing commitments over this period exceed $3.65 billion.
Since the 2017 Tax Cuts and Jobs Act became law, Amgen reports investing more than $40 billion in manufacturing infrastructure and research and development activities.
Navigating Tariff Challenges
This investment announcement arrives as international pharmaceutical manufacturers confront mounting pressure from the Trump administration regarding drug imports.
President Trump issued an executive order in April establishing 100% tariffs on branded prescription medications imported into the United States, unless pharmaceutical companies agreed to government drug-pricing negotiations or pledged domestic manufacturing commitments.
Amgen’s enhanced domestic manufacturing presence strategically positions the organization to address these regulatory pressures, although company representatives characterized the Puerto Rico expansion as an element of comprehensive, long-term supply chain planning.
Puerto Rico, which holds U.S. territory status, has served as a pharmaceutical manufacturing center for more than six decades and hosts numerous major drug manufacturer operations.
The Juncos facility has functioned as part of Amgen’s production network since 1992 and maintains a critical position in the company’s worldwide biologics distribution system.
Amgen has not disclosed a definitive completion timeline for the most recent Puerto Rico expansion project.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
